STAT+: AACR in 30 Seconds Highlights Revolution Medicines and RAS Inhibitors

22 Apr 20264 min read0 viewsVerified Feed

GIST

You’re reading the web version of STAT’s popup newsletter, AACR in 30 seconds, your guide to what’s happening at the American Association of Cancer Researchers’ annual meeting. This is the last edition of our pop-up newsletter.

We hope you’ve learned as much as we have. If you’re not already a STAT+ subscriber, consider it!

There’s currently a  60% off promotion  on annual subscriptions. In the meantime, thanks for joining us.

Overcoming resistance and RevMed’s next drug? In case you missed it, Revolution Medicines’ sessions yesterday were jam-packed with conference attendees.

While most of the media coverage focused on the daraxonrasib in frontline pancreatic cancer data, the company also revealed some activity in a new compound, RM-055. CEO Mark Goldsmith described it as being part of a new class of “catalytic inhibitors,” since it can slice off a phosphate from GTP-RAS, or the “on” form of RAS, and turn the protein off.

Clinical Editorial

Overview and scope

The report summarizes highlights from a STAT News recap of sessions at the AACR annual meeting, focusing on corporate updates and emerging agents in oncology.
The material is a synthesis of conference activity rather than a primary research article with trial data.

Design and emphasis of coverage

The narrative centers on Revolution Medicines’ conference presentations, emphasizing both a known frontline pancreatic cancer signal and information about a novel compound.
Attention is drawn to a potential mechanistic distinction described by the company as a new class of catalytic inhibitors, labeled RM-055.

Agent and mechanism sketch

RM-055 is described as capable of cleaving a phosphate from GTP-bound RAS, effectively targeting the active “on” form of RAS.
The proposed mechanism suggests ability to reduce activity across multiple mutant RAS proteins, addressing a resistance pathway where cancer cells sometimes amplify mutant RAS to undermine inhibitors.

Clinical implications and framing

The report frames RM-055 as potentially advancing the ongoing effort to mitigate resistance seen with RAS-directed therapies, proposing that catalytic activity may complement existing approaches.
The discussion situates RM-055 within a broader arms race against RAS-driven cancers, particularly those reliant on mutant RAS signaling.

Limitations and reporting notes

The source provides a high-level conference summary without presenting trial results, specific design details, patient populations, or quantitative outcomes for RM-055.
It highlights interest generated by the catalytic mechanism but does not supply independent corroboration or long-term safety data.